End Depression News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamemmay assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2022 /PRNewswire/ Actinogen Medical Limited (ASX: ACW)is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment. Dr Steven Gourlay, Actinogen's CEO and MD, said: "We are very pleased to announce the formal start of our trial in patients with MDD and cognitive impairment who are inadequately treated by their current anti-depressant medication. There is a strong scientific rationale for reduc

New south walesUnited statesSteven gourlayActinogen medical limitedMajor depressive disorderCogstate cognitive test batteryMontgomery asberg depression rating scaleFragilex syndromeApproximately 5 of americans suffer from major depressive disorder mddwhich is commonly associated with quot foggy thinking buta new clinical trial raises hope that oncea day oral drug xanamemmay assist where treatment by anti depressant medication alone inadequate sydneyDec 14022 prnewswire actinogen medical limited asx acw is pleased to announce that the first patient has been randomized and treated in xanacidd phase 2 depression clinical trial will measure effects of xanamem on safetyOgnitive performance and depression in patients who are inadequately treated by their anti depressant medication have both depressive symptoms cognitive impairment dr steven gourlayCtinogen 39s ceo and mdAid quot we are very pleased to announce the formal start of our trial in patients with mdd and cognitive impairment who inadequately treated by their current anti depressant medication there isa strong scientific rationale for reducing brain cortisol levels improve symptoms depression xanamem has already been proven enhance cognition three independent clinical trials safety demonstrated more than 300 volunteers date potential be an effective low dose daily oral therapy treatmentLzheimer 39s disease and many other neurological conditions where it may be used alone or in combination with treatments quot the xanacidd phase 2 depression trial isa six week proof of concept